Neurology Clinical Trials Market By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication (Alzheimer’s Disease, Parkinson’s Disease, Epilepsy, Stroke, Multiple Sclerosis, Migraine, Others), By End-User (Pharmaceutical & Biotech Companies, Hospitals & Clinics, Contract Research Organizations (CROs), Academic & Research Institutes, Government & Non-profit Organizations, Others), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles and Market Forecast, 2025–2035

---

What trends will shape the Neurology Clinical Trials Market in the coming years?

The Neurology Clinical Trials Market accounted for USD 5.89 Billion in 2024 and USD 6.27 Billion in 2025 is expected to reach USD 11.78 Billion by 2035, growing at a CAGR of around 6.5% between 2025 and 2035. The increase in the use of the decentralized and virtual trial models in the neurology clinical trials market will enhance patient recruitment and retention by means of remote monitoring. Machine learning and artificial intelligence will have a greater role in patient characterization, predictive analysis, and individual interpretation of real-time data. Personalized and disease-modifying interventions to address conditions such as Alzheimer's and Parkinson's will become a growing focus driving personalized trials.

The number of collaborations between pharmaceutical companies, CROs, and academic institutions will increase in order to move innovation quicker. Regulatory authorities are giving accelerated approvals and friendly guidelines to the research of neurological conditions. The increasing incidence of neurodegenerative diseases is likely to drive demand for large-scale studies. Collectively they will lead to new innovation, efficiency, and patient-centricity in neurology clinical trials.

What do industry experts say about the Neurology Clinical Trials Market trends?

“We are excited about the possibilities and are committed to advancing our research for the prospective benefit of patients living with these challenging neurological conditions.”

• Cory Nicholas, CEO of Neurona Therapeutics.

“Focusing on enhanced targeting and screening has not only helped us overcome the challenges in supporting more difficult trials, but has also improved the overall experience for our patients, reinforcing our commitment to their well-being and the success of our studies.”

• Jill Pellegrino, CEO of AutoCruitment.

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Neurology Clinical Trials Market?

How does increasing neurodegenerative disease prevalence accelerate demand for innovative neurology trials?

The Neurology Clinical Trials Market is experiencing a surge in demand as there is a rising prevalence of neurodegenerative diseases, which are increasing the need to have better treatment options. The need to provide care to patients with Alzheimer's disease is overwhelming, as the U.S. National Institute on Aging estimates the current burden in the country at over 6 million citizens. This increase in cases is encouraging the generation of new forms of treatment that are not only palliative but also directed towards disease modification. Neurological clinical trials are now taking on more decentralized and virtual models to make their studies accessible to patients in more geographical locations.

The high patient population ensures improved patient recruitment and more confident results, thus enhancing research validity. Pharmaceutical/biotechnology companies are spending a lot of money developing pipelines of drugs to treat Parkinson's, multiple sclerosis, and epilepsy. Funding and government initiatives are also helping enhance the fast-forwarding of neurology-oriented clinical research. Digital health technologies are used with patient-centric trial designs as they overcome participation and compliance challenges. The increasing cost of these conditions indicates the medical need in the population. Finally, the increasing nature of neurodegenerative diseases is one of the factors contributing to the enhancement of innovations and growth within this market.

Why is rising pharmaceutical R&D investment driving expansion within neurology-focused clinical studies?

Factors such as increasing pharmaceutical research and development investment are driving growth in the Neurology Clinical Trials Market, as it allows bringing to market new therapies to treat neurological disorders. According to the U.S. National Institutes of Health, the funding of the research of neurological diseases amounts to more than 3.1 billion dollars, informing the large investment into the improvement of treatments. This additional funding permits businesses to aim at the advanced conditions like Alzheimer's, Parkinson's, multiple sclerosis, and rare neurodegenerative disorders. The increased investment allows more multicentric and multiphase clinical trials and enhances its research results.

The pharmaceutical companies are incorporating the use of new technology, including AI-enabled analytics and electronic observation of the patients, to facilitate better trial efficiency. The provision of more resources also facilitates the recruitment of special investigators and the creation of trial networks in various regions. There are increased partnerships in public-private collaborations by merging knowledge and resources to maximize research performance. Increased investments in R&D help speed the processes of finding the disease-modifying therapies instead of just symptom-controlling treatments. Patient-centered trial designs are increasingly becoming practical with increased participation, retention, and reliability of the data. In general, the growth in the level of pharmaceutical research and development investment is a key force that is increasing the scope, innovativeness, and reach of clinical studies in the neurology field.

How do high operational costs create barriers for conducting global neurology trials?

High operational expenses have an adverse effect on the growth of the neurology clinical trials market because they reduce the practicality of multi-country large-scale clinical trials. Costs associated with patient recruitment, management of sites, and regulatory/compliance issues are very substantial in neurology given the inherent complexity of diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. More sophisticated diagnostic instruments, neuroimaging, and biomarkers add even more to the trial expenses. Conducting clinical trials in multiple geographical locations also poses logistic issues such as staff training, control of quality, and integration of clinical data. The expansiveness of the costs is also a factor limiting access to specialized investigators and facilities of the highest standards in emerging markets.

The cost or the tendency of regulatory differences among the countries may raise administrative costs and delay trial periods. Lack of budget funds often puts small and mid-sized pharmaceutical companies at a disadvantage, thus minimizing their involvement in international trials. The costs associated with the operations may also restrict the number of patients being reached and affect recruitment and retention. These are financial obstacles that slow down the innovations and the pace of developing new therapies. Overall, the high cost of operation continues to be a major bottleneck limiting the expansion and size of international neurology clinical trials.

How can decentralized trial models enhance accessibility for participants across diverse geographies?

The Neurology Clinical Trials Market is gradually embracing decentralized trial designs as a way of making trials accessible to participants in different geographies. Such models give the patients flexibility to be part of the process without necessarily having to travel frequently to the hospital, and that is of much significance to patients with mobility impairment or those in the rural part of the country. Complex data may be collected digitally, including telemedicine visits, monitoring wearables, and electronic patient-reported outcomes, continuously and in real time.

Decentralized trials diversify the pool of participants, making more varied study populations possible to create and more likely to contribute to the reliability and generalizability of trial outcomes. Other pharmaceutical/biotech companies enjoy reduced logistical expenses such as management of sites and travel reimbursement. Regulatory agencies are promoting virtual trial techniques, using guidelines to demonstrate how information on patient safety and data integrity can be maintained. Patients feel more convenience and compliance, which leads to an increased retention and an improved efficiency of the study. Integration with mobile health applications and wearable technologies enables continuity to monitor the health of the patient. Multi-center implementation is streamlined where trial implementation becomes less physical. In general, decentralized trials are changing the future of neurology clinical research by making it patient-centric, efficient, and inclusive.

Why will personalized medicine innovations unlock breakthroughs in neurology disorder targeted therapies?

The advancements in the neurology clinical trials market are quite noticeable because of personalized medicine advancements, which enable adjusting therapies to a particular patient with regard to genetic factors, biomarkers, and specificities of the disease. Precision medicine is led in patient stratification to ensure that viable drugs under clinical trials reach individuals most likely to respond, lower the failure rate in clinical trials, and increase the efficacy of effective medical products in a complex disease such as Alzheimer's, Parkinson's, multiple sclerosis, and epilepsy. The method can also identify new disease-modifying targets, and this leads to the fast tracking of the development of novel therapies. The latest technologies in genomic sequencing, proteomics, and advanced neuroimaging are the cutting-edge tools that give specific details that direct a personalized approach to treatment.

Biomarker-guided trials are becoming increasingly popular as drug companies attempt to create protocols that will reduce adverse events, maximize dosing, and increase patient outcomes. Tailored methods enable reducing the size of trials and making trials more efficient, without losing statistical power. Regulatory agencies are facilitating adaptive trial design and the framework that can support precision medicine. The combination of wearable devices and digital health solutions enables the constant tracking of patient responses. It takes less time to make decisions and speed up the pace of clinical development as data analytics improves. Generally, the concept of personalized medicine is transforming neurological clinical research by making the actual medications more patient-specific and focusing.

What are the key market segments in the Neurology Clinical Trials industry?

Based on the phase, the Neurology Clinical Trials Market is classified into Phase I, Phase II, Phase III, and Phase IV. The objective of the Phase I trials is to monitor safety and tolerability and dosage among small groups of patients, which is the key to further studies. Phase II trials that had the greatest market share test the efficacy and short-term side effects, and these are most instrumental in determining the success of drug development. Phase III trials test more cases of patients to validate the effectiveness of the therapy and estimate adverse incidents, which can be used in the approval process.

Phase IV trials provide long-term safety and efficiency within the actual world contexts after commerce. The dominance of Phases II and III indicates the high need for efficacy-based results in the perspective of neurological diseases. An ever-greater number of investments in the initial stages will lead to greater innovation, whereas post-marketing surveillance will help maintain patient safety. In general, every stage plays its own role in the development of the promising new neurology treatment and the area of market expansion.

Based on the indication, the Neurology Clinical Trials Market is classified into Alzheimer’s disease, Parkinson’s disease, epilepsy, stroke, multiple sclerosis, migraine, and others. The Neurology Clinical Trials Market is extremely dominated by the Alzheimer's disease trials due to the urgent need to discover disease-modelling drugs. Parkinson's disease comes second as another fundamental area of study, finding enhancements to the motor functionality coupled with inhibiting disease advancement.

Epilepsy studies are becoming popular as there has been an improvement of anti-seizure medications or novel drug delivery systems. Multiple sclerosis continues to represent a key target area with good regulatory approvals of immunomodulating drugs. New trials due to stroke are emerging and would include neuroprotection and rehabilitative strategies. The market has been leading to the growth of migraine trials fueled by the interest in next-generation preventive and acute products. Besides, rare neurological diseases, such as ALS and Huntington disease, are emerging interest areas, backed by orphan drug incentives and precision medicine programs.

Which regions are leading the Neurology Clinical Trials Market, and why?

The North America Neurology Clinical Trials Market is leading due to its great investment in R&D and the rich funding of agencies such as the National Institute of Neurological Disorders and Stroke (NINDS). A sound regulatory system provided by the FDA ensures approvals to be made easily, which will encourage the conducting of more neurology-related trials. Increasing incidence of Alzheimer's, Parkinson's, and multiple sclerosis is further stimulating trial activity.  

Implementation of an AI-based and decentralized trial paradigm boosts efficiency of patient recruitment and collection of data. Canada is also playing a major role through the increasing interest towards clinical research partnerships and governmental support. Patient awareness is high, and there is good clinical trial participation in the region, which makes it more competitive. In general, North America is the hotspot of neurology-related innovation and commercialization of clinical trials.

The Asia Pacific Neurology Clinical Trials Market is growing due to the with a large number of patients with neurological disorders and the increasing burden of an aging population. Countries such as China, India, Japan, and South Korea are becoming emerging clinical trial centers on the basis of cost benefits and growing research facilities. Governments are equipping them with favorable policies, funding, and regulatory reforms in order to encourage the entry of global pharmaceutical companies and CROs.

Increasing access to experienced researchers and sophisticated hospital networks is also increasing trials. There is growing uptake of technology in digital health and new models of decentralizing trials, which are making access and patient recruitment more efficient. Japan has been the international leader in innovation in neurology workplace research, indicating that China and India are fast developing their trial volumes. The ecosystem is being boosted by increasing cross-sector partnerships between native and foreign actors. In general, Asia-Pacific is likely to secure the highest CAGR, hence coming in as a dominant driver of neurology clinical trials.

What does the competitive landscape of the Neurology Clinical Trials Market look like?

The Neurology Clinical Trials Market is highly competitive, involving big pharmaceutical firms across the globe, and dominant and major CROs. Such large players as Novartis, Biogen, Roche, Eli Lilly, AbbVie, Sanofi, Merck, GSK, AstraZeneca, Eisai, and Teva are also on a spending spree in trying to advance their neuro pipeline in the Alzheimer's, Parkinson's, epilepsy, and multiple sclerosis fields. End-to-end services across phases are provided by Contract Research Organizations (CROs) such as IQVIA, Syneos Health, Icon plc, Labcorp, Medpace, Covance, and Charles River, which dominate the outsourcing of trial management. Technology-savvy contract research organizations include Medidata and IXICO, which assist trial sponsors with platforms/services based on emerging technologies, AI-enabled data management, and neuroimaging.

The trend in collaborations between pharma, CROs, and academic institutions is quickening innovation and decreasing trials. The rise in usage of decentralized and virtual trial models is restructuring the competitive environment by enhancing access to and recruitment of patients. The common business models are strategic alliances and licensing agreements with the aim of building up an extensive neurology portfolio. Newer biotechnology companies are building momentum by focusing on specially targeted treatments of rare neurological conditions. A recent trend can be seen as Takeda initiates the idea of making India a hub of global trials because of the availability of a large patient pool, cost competitiveness, and growing healthcare infrastructure. This is a stride taken by businesses as they strategically enter the emerging markets to fast-track drug development and gain growth potential in neurology clinical trials.

Neurology Clinical Trials Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Neurology Clinical Trials industry?

• In May 2025, Sanofi announced a $470 million acquisition of Vigil Neuroscience to gain control of Vigil's oral Alzheimer's candidate, VG-3927, a TREM2 agonist aimed at enhancing microglial function. The deal includes a non-transferable contingent value right (CVR) for Vigil shareholders, entitling them to $2 per share upon the first commercial sale of VG-3927. Sanofi had previously made a strategic $40 million investment in Vigil in June 2024, which included a right of first negotiation for VG-3927. The acquisition does not include Vigil's other clinical candidate, VGL101, which is excluded from the deal.
• In April 2025, AbbVie released promising Phase 3 results for tavapadon, an experimental Parkinson's disease drug that showed significant improvements in motor symptoms and a good safety profile. The drug, a partial agonist for dopamine D1 and D5 receptors, successfully met its primary endpoints in early-stage Parkinson's patients and is expected to be submitted for FDA approval in 2025. Tavapadon targets D1/D5 receptors, which are less prone to the impulse control disorders and excessive sleepiness associated with older D2/D3 agonists, offering a new treatment pathway.

Report Coverage:

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Study Design

• Interventional
• Observational
• Expanded Access

By Indication

• Alzheimer’s Disease
• Parkinson’s Disease
• Epilepsy
• Stroke
• Multiple Sclerosis
• Migraine
• Others

By End-User

• Pharmaceutical & Biotech Companies
• Hospitals & Clinics
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Government & Non-profit Organizations
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Novartis International AG
• Biogen Inc.
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• AbbVie Inc.
• Sanofi S.A.
• Merck & Co., Inc.
• GlaxoSmithKline plc (GSK)
• AstraZeneca plc
• Eisai Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Bayer AG
• Johnson & Johnson Services, Inc.
• Takeda Pharmaceutical Company Limited.

Frequently Asked Questions (FAQs)